This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1996;275(8):582.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

TWO NEW changes in childhood immunization are imminent: extension of the acellular pertussis component in the diphtheria and tetanus toxoids and pertussis (DTP) vaccine to the first three doses given at 2,4, and 6 months of age, and the advent of a new and highly potent vaccine against hepatitis A.

The Vaccines and Related Biological Products Advisory Committee of the Food and Drug Administration (FDA) has agreed that the acellular form of the pertussis vaccine is effective and, insofar as it can be ascertained, safe when incorporated into the first three doses of DTP vaccine. Until now, because of lack of evidence that it was sufficiently immunogenic in infants, the acellular form of this vaccine was restricted to DTP immunizations in older children.

At the same meeting, the committee agreed unanimously that a new type of vaccine against hepatitis A was safe and effective and could be licensed.

The FDA . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?